A2RR34 Stock Overview
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Arrowhead Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$14.28 |
52 Week High | US$24.85 |
52 Week Low | US$14.28 |
Beta | 0.72 |
1 Month Change | -17.27% |
3 Month Change | -31.31% |
1 Year Change | -36.19% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -58.69% |
Recent News & Updates
Recent updates
Shareholder Returns
A2RR34 | BR Biotechs | BR Market | |
---|---|---|---|
7D | -13.7% | -0.3% | 0.5% |
1Y | -36.2% | -4.8% | 16.7% |
Return vs Industry: A2RR34 underperformed the BR Biotechs industry which returned -5.7% over the past year.
Return vs Market: A2RR34 underperformed the BR Market which returned 17.9% over the past year.
Price Volatility
A2RR34 volatility | |
---|---|
A2RR34 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 9.5% |
Market Average Movement | 4.7% |
10% most volatile stocks in BR Market | 8.6% |
10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: A2RR34's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine A2RR34's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 525 | Chris Anzalone | arrowheadpharma.com |
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases.
Arrowhead Pharmaceuticals, Inc. Fundamentals Summary
A2RR34 fundamental statistics | |
---|---|
Market cap | R$14.88b |
Earnings (TTM) | -R$1.54b |
Revenue (TTM) | R$943.70m |
15.4x
P/S Ratio-9.4x
P/E RatioIs A2RR34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A2RR34 income statement (TTM) | |
---|---|
Revenue | US$181.74m |
Cost of Revenue | US$0 |
Gross Profit | US$181.74m |
Other Expenses | US$478.55m |
Earnings | -US$296.81m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
Earnings per share (EPS) | -2.40 |
Gross Margin | 100.00% |
Net Profit Margin | -163.32% |
Debt/Equity Ratio | 157.6% |
How did A2RR34 perform over the long term?
See historical performance and comparison